Articles tagged with Tumor Growth
Using artificial human skin, researchers have successfully blocked invasive growth in a skin cancer model by targeting the TGF beta pathway. The study aims to develop new skin cancer therapies using existing drugs that can block these signalling pathways.
Scientists at Cold Spring Harbor Laboratory have found a way to reprogram cells causing Ewing sarcoma to behave like normal connective tissue cells. By blocking the protein ETV6, cancer cells can be forced to take on a new identity and grow less aggressively.
Researchers found that certain gene signaling pathways, such as interferon γ and beta-catenin, can lead to tumor hyperprogression after immunotherapy. Targeting these pathways may prevent hyperprogression in preclinical models.
Researchers found that regorafenib, a dual PDGFR α/β inhibitor, modifies the cancer microenvironment and enhances the efficacy of anti-PD-1 immunotherapy in advanced gastric cancers. This combination therapy boosts tumor infiltrating immune cells and reduces tumor fibroblasts.
A study of 184 grade I and II meningiomas found associations between specific tumor mutations and increased or decreased recurrence rates. Mutations in ATM and CREBBP were linked to accelerated recurrence, while POLE mutations showed protective effects, highlighting potential targets for intervention.
A computational model predicts brain tumour growth using MRI data, providing valuable insights for clinicians. The study uses anonymous patient data to develop a predictive model for glioblastoma multiforme (GBM) growth, which can be used to inform treatment decisions.
Researchers found that inhibiting HSF1 signaling reduces hepatoblastoma growth and induces apoptosis, suggesting it as a viable pharmacologic target. The study also identified HSF1's role in tumor aggressiveness and its potential association with mortality.
Researchers found that EWS::FLI1 induces Slit2 expression, which activates Robo receptors and enhances Ewing sarcoma growth. Silencing Slit2 strongly inhibited Ewing sarcoma cell growth, providing an opportunity for targeted therapy.
A new method utilizes an unnatural sugar to anchor cytokines to T cells, enhancing their functions without systemic side-effects. The approach has shown promise in stimulating the host immune system against tumor cells and inhibiting tumor growth in mice with melanoma.
Researchers are working to understand the events contributing to pancreatic cancer development by studying gene abnormalities and their effects on the disease. Dr. Krushna Patra's lab is focused on understanding how genetic mutations like GNAS contribute to pancreatic cancer growth.
Researchers identified key metabolic pathways in tumor-associated macrophages that contribute to cancer development and progression. Targeting these pathways may provide a new perspective for immunotherapy-based cancer treatments.
Researchers tracked 392 patients with diffuse low-grade glioma over 20 years and found that aggressive surgical removal offered a distinct survival advantage. Smaller tumor sizes were associated with longer survival times, highlighting the importance of early intervention.
A team of researchers identified a population of 'cheating' cancer cells that can bypass constraints imposed by lack of oxygen, allowing them to continue growing. These cells manipulate the HIF-1 protein, which normally slows down cell growth under hypoxic conditions.
A new study from Edith Cowan University found that a single bout of exercise can significantly suppress tumour growth in people with late-stage prostate cancer. The researchers observed increased levels of anti-cancer myokines after high-intensity exercise, which helped fight cancerous cells and stimulated anti-cancer processes.
Researchers found that simultaneously targeting two signalling switches can severely inhibit tumour angiogenesis, cancer growth and metastasis in multiple models of cancer. This approach has the potential to restrict a cancer's ability to escape therapy by rapidly destroying the VEGF receptor when both receptors are targeted.
Dr. Keith Chan joins Houston Methodist to enhance chemoimmunotherapy responses in bladder cancer, while also expanding research into pancreatic and skin cancers. He will lead translational research and mentor next-generation cancer researchers.
Researchers found that activating the non-mutated form of P53 can change the fundamental makeup of cancer stem cells in mouse models of mucoepidermoid carcinoma. This new therapy approach shows promise for treating this lethal form of salivary gland cancer.
Researchers at UNIGE and LMU discovered that immune system's anti-tumour activity peaks in the morning. Tumours implanted at night grew faster than those implanted in the afternoon. Administering immunotherapy treatments early morning significantly enhanced their effectiveness, suggesting a new strategy for cancer treatment.
A study published in Nature reveals that cancer stem cells' miscommunication with their environment can trigger a self-perpetuating series of events leading to malignancy. Leptin signaling plays a surprising role in this process, which could be blocked to prevent tumor progression.
Researchers review myeloid-derived suppressor cells' phenotypes, mechanisms of immunosuppression, and roles in cancer treatment. Studies on non-malignant diseases, such as autoimmune disorders and obesity, are lacking, highlighting the need for further investigation.
A new study reveals that the protein fragile X mental retardation protein (FMRP) plays a crucial role in helping tumors evade immune destruction, leading to treatment resistance. FMRP regulates a network of genes and cells in the tumor microenvironment, contributing to its ability to hide from immune cells.
Scientists at Northwestern Medicine have discovered a causal link between environmental phthalates and increased uterine fibroid growth. Exposure to certain phthalates, such as DEHP, may activate a hormonal pathway that causes fibroid tumors to grow. This study explains the mechanisms behind this association.
Opaganib, an oral small molecule pill, shows potential as a nuclear radiation injury therapeutic for homeland security medical countermeasures and antitumor radiotherapy. The compound protects normal tissue from radiation damage and improves antitumor activity and response to chemoradiation.
Researchers found variable voltages in breast cancer cell membranes, which may indicate an electrical communication network between cells. This discovery could lead to new treatments by disrupting this network, potentially making cancer cells easier to treat.
Researchers discovered that the Memo1 protein binds copper ions, blocking toxic redox reactions that damage or kill cancer cells. The protein's interaction with copper also protects against metastasis formation in breast cancer cells. This finding opens up potential new treatments for cancer.
Researchers have discovered that targeting a specific mutation in fibrolamellar tumors can reduce tumor growth in mice, offering a promising approach to treating this nearly incurable cancer. The findings highlight the potential for novel therapies against an intractable disease.
Researchers at the University of Pittsburgh School of Medicine have discovered a genetic link between melanoma tumors and telomere maintenance, which could lead to new treatments for the disease. The study found that mutations in the TPP1 gene stimulate telomerase activity, promoting long telomeres that enable cancer cells to divide in...
Researchers found that excessive iron accumulation accelerates tumor growth in F. nucleatum-positive colorectal cancer by enhancing inflammatory responses in immune cells, promoting interpatient prognostic variability. Iron levels also modulate macrophage expression profiles, transforming them into pro-tumor cells expressing CCL8.
Researchers identified a key protein called TLR2 that predicts patient survival in lung cancer, which also activates as a tumor suppressor response in non-small cell lung cancer. A drug compound that activates TLR2 reduced tumour growth in mice and shows promise for earlier detection and improved patient outcomes.
Researchers have discovered two novel drugs that can block the growth and shrink the size of schwannoma tumors, a type of nerve sheath tumor found in the nervous system. The treatment works by inhibiting the Hippo signaling pathway, which is dysregulated in multiple types of cancer.
A study reveals that interleukin 34 (IL-34) modulates the balance between two myeloid-derived suppressor cell populations, leading to immunosuppression and chemoresistance in triple-negative breast cancer. Neutralizing IL-34 with a drug reduces tumor growth and susceptibility to chemotherapy.
A new method of modifying our immune system has been demonstrated in a study published in Advanced Science, which could help treat skin cancer.
In the ARROS-1 trial, 48% of patients achieved partial responses to NVL-520, with responses seen across all dose levels and in heavily pre-treated patients. The treatment also showed promise for brain metastases, with three out of three patients experiencing measurable response or no emergence of new metastases.
A new experimental drug has shown promising results in treating liver cancer, with two patients experiencing a partial response to the treatment. The drug, NMS-01940153E, targets an enzyme that plays a critical role in cell division and growth, and its side effects are manageable.
A new study reveals that urolithin A from pomegranates can rejuvenate T cells by recycling and renewing mitochondria, enhancing their ability to fight tumors. The researchers plan to investigate the application of urolithin A in clinical trials for colorectal cancer.
Researchers have found a drug that targets the key, cancer-causing gene MYC has been able to inhibit its function safely and effectively. Eight out of 12 patients showed stabilisation of disease after treatment with OMO-103, with one patient experiencing a reduction in tumour-derived DNA circulating in the blood stream.
Researchers discovered a molecular link between disrupted circadian rhythms and lung tumor growth, implicating a cancer-signature gene known as HSF1. Disrupted clocks may trigger lung tumors in individuals with irregular sleep patterns or night shifts.
A recent study by Weill Cornell Medicine investigators found that corrupted endothelial cells can protect leukemia cells from chemotherapy drugs. The discovery has the potential to improve drug discovery programs and clinical trials for T-cell acute lymphoblastic leukemia (T-ALL) patients.
Researchers at LSU Health New Orleans have identified a new drug target for triple-negative breast cancer, which lacks estrogen and progesterone receptors. The novel small molecule inhibitor NSC33353 works synergistically with doxorubicin to suppress the growth of TNBC cells.
Researchers at Mount Sinai's Tisch Cancer Institute have discovered a new gene, PDZK1IP1, essential to colon cancer growth. The study found that surrounding inflammation activates the super enhancer, promoting tumor cell survival and growth.
A large multi-center study analyzing patient records from three major cancer centers found that ILC is detected later and has worse outcomes than IDC. The research highlights the need for new imaging technologies to improve early detection of ILC, which often spreads beyond breast tissue before diagnosis.
The study reveals how the activating partner PI5P interacts with two different regions of regulatory protein UHRF1, showing its role in modulating complex proteins. This finding could breathe new life into the search for UHRF1-directed medicines.
A new study has uncovered a previously unknown genetic process that could inform the development of novel treatment options for glioblastoma (GBM), a virtually incurable brain tumor. The epidermal growth factor receptor (EGFR) signaling pathway and long non-coding RNA molecules, such as lncEPAT, play critical roles in GBM tumorigenesis.
A new epigenetics drug, tazemetostat, has been found to stop bladder cancer growth by activating the immune system, not just inhibiting tumors. The drug targets the EZH2 gene and is being tested in clinical trials for late-stage bladder cancer.
Researchers found that the quality and mix of collagen in pancreatic ductal adenocarcinoma tumors affects prognosis. Patients with tumors containing cleaved Collagen I experienced poor survival prospects, while those with non-cleaved Collagen I had better outcomes.
Researchers have developed a method to synthetically produce EBC-46, a cancer-fighting compound, using an abundant plant-based starting material. This breakthrough could lead to new treatments for various diseases, including AIDS and Alzheimer's disease.
Researchers developed a computational platform to identify metabolic vulnerabilities in ovarian cancer genes, suggesting opportunities for targeted therapies. The study found that certain genetic alterations can create vulnerabilities in cancer cell metabolism, which can be exploited to selectively kill cancer cells.
Researchers at the University of Helsinki have identified target genes of the MYC oncogene responsible for its growth-promoting effects. By modifying these genomic binding sites, they slowed down cell growth. This finding has significant implications for developing new cancer treatments.
Scientists successfully inhibited cancer cell growth using a modified pyrrolizidine alkaloid that avoids liver damage. The approach uses 'on-site synthesis' near cancer cells to limit toxicity.
A new biomarker called SPRIGHTLY could distinguish between two aggressive types of brain tumors in children: Group 3 and Group 4 medulloblastomas. The biomarker is highly expressed in Group 4 medulloblastomas, which have a poorer prognosis.
Researchers discovered a type of triple-negative breast cancer cell that can trigger dormancy, evading therapies and allowing for efficient survival in distant organs. This finding highlights the need for more selective therapeutic strategies targeting both dividing and invasive dormant cells.
A new study provides valuable insights into the roles of B cells and plasma cells in early-stage lung cancer biology, highlighting their influence on tumor development and treatment outcomes. The research also reveals environmental factors and molecular features that contribute to the landscape of infiltrating immune cells.
Researchers at Mayo Clinic Comprehensive Cancer Center found that metabolic imaging, combined with traditional treatment response assessment methods, can provide critical information to guide therapy for pancreatic cancer patients. The use of positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) tracer adds significant pr...
Researchers at Tel Aviv University develop a groundbreaking method to eradicate glioblastoma brain tumors by targeting astrocytes and starving them of energy. The study found that in the absence of these brain cells, tumor cells die and are eliminated, offering a promising basis for developing effective medications.
Researchers at the University of Gothenburg have identified a protein called HnRNPK that controls tumor growth by binding to messenger RNA, potentially enabling the development of new cancer drugs with fewer side effects.
Researchers at Karolinska Institutet have developed a potential curative treatment for neuroblastoma, using DHODH blockers in combination with chemotherapy to cure mice with the disease. The treatment has shown promising results and could improve survival rates for children with neuroblastoma.
Researchers at Kyoto University have developed a cancer therapy model that utilizes a protein degrading system to transiently degrade and reduce the PD-1 protein, which blocks immune function. This approach has shown high therapeutic efficacy in inhibiting cancer cell growth in mice.
A study found that cold temperatures activate brown adipose tissue that competes with tumors for glucose, inhibiting tumor growth and prolonging survival. Researchers suggest that cold therapy could be a promising approach to cancer therapy.
A new study by Tokyo University of Science researchers reveals that dendritic cell immunoreceptor (DCIR) plays a crucial role in the development of colorectal tumors. Blocking DCIR may prevent ulcerative colitis and colon cancer, offering a potential therapeutic target for treating these diseases.
A team of researchers has discovered that malignant tumors accumulate lipid delivery molecules called LDL and attract immune suppressor cells called neutrophils, leading to tumor progression. The study also shows that targeting the LOX-1/oxidized LDL axis may be a promising strategy for treating both cancer and cardiovascular disease.